214 related articles for article (PubMed ID: 16335918)
1. 1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.
Catarzi D; Colotta V; Varano F; Lenzi O; Filacchioni G; Trincavelli L; Martini C; Montopoli C; Moro S
J Med Chem; 2005 Dec; 48(25):7932-45. PubMed ID: 16335918
[TBL] [Abstract][Full Text] [Related]
2. 4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Lenzi O; Colotta V; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Varani K; Marighetti F; Morizzo E; Moro S
J Med Chem; 2006 Jun; 49(13):3916-25. PubMed ID: 16789747
[TBL] [Abstract][Full Text] [Related]
3. 1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.
Colotta V; Catarzi D; Varano F; Calabri FR; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Deflorian F; Moro S
J Med Chem; 2004 Jul; 47(14):3580-90. PubMed ID: 15214785
[TBL] [Abstract][Full Text] [Related]
4. Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study.
Morizzo E; Capelli F; Lenzi O; Catarzi D; Varano F; Filacchioni G; Vincenzi F; Varani K; Borea PA; Colotta V; Moro S
J Med Chem; 2007 Dec; 50(26):6596-606. PubMed ID: 18047262
[TBL] [Abstract][Full Text] [Related]
5. 2-aryl-8-chloro-1,2,4-triazolo[1,5-a]quinoxalin-4-amines as highly potent A1 and A3 adenosine receptor antagonists.
Catarzi D; Colotta V; Varano F; Calabri FR; Lenzi O; Filacchioni G; Trincavelli L; Martini C; Tralli A; Montopoli C; Moro S
Bioorg Med Chem; 2005 Feb; 13(3):705-15. PubMed ID: 15653338
[TBL] [Abstract][Full Text] [Related]
6. Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Colotta V; Lenzi O; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Traini C; Pedata F; Morizzo E; Moro S
J Med Chem; 2009 Apr; 52(8):2407-19. PubMed ID: 19301821
[TBL] [Abstract][Full Text] [Related]
7. 1,2,4-triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A₃ receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies.
Catarzi D; Varano F; Poli D; Squarcialupi L; Betti M; Trincavelli L; Martini C; Dal Ben D; Thomas A; Volpini R; Colotta V
Bioorg Med Chem; 2015 Jan; 23(1):9-21. PubMed ID: 25497490
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.
Pastorin G; Da Ros T; Bolcato C; Montopoli C; Moro S; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
J Med Chem; 2006 Mar; 49(5):1720-9. PubMed ID: 16509587
[TBL] [Abstract][Full Text] [Related]
9. New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Colotta V; Catarzi D; Varano F; Capelli F; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Pedata F; Schiesaro A; Morizzo E; Moro S
J Med Chem; 2007 Aug; 50(17):4061-74. PubMed ID: 17665891
[TBL] [Abstract][Full Text] [Related]
10. 5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists.
Da Settimo F; Primofiore G; Taliani S; Marini AM; La Motta C; Simorini F; Salerno S; Sergianni V; Tuccinardi T; Martinelli A; Cosimelli B; Greco G; Novellino E; Ciampi O; Trincavelli ML; Martini C
J Med Chem; 2007 Nov; 50(23):5676-84. PubMed ID: 17927167
[TBL] [Abstract][Full Text] [Related]
11. 1,2,4-Triazolo[1,5-a]quinoxaline derivatives: synthesis and biological evaluation as adenosine receptor antagonists.
Catarzi D; Colotta V; Varano F; Filacchioni G; Martini C; Trincavelli L; Lucacchini A
Farmaco; 2004 Feb; 59(2):71-81. PubMed ID: 14871498
[TBL] [Abstract][Full Text] [Related]
12. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.
Cheong SL; Dolzhenko A; Kachler S; Paoletta S; Federico S; Cacciari B; Dolzhenko A; Klotz KN; Moro S; Spalluto G; Pastorin G
J Med Chem; 2010 Apr; 53(8):3361-75. PubMed ID: 20307065
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of analogues of 7-chloro-4,5-dihydro-4- oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic acid (TQX-173) as novel selective AMPA receptor antagonists.
Catarzi D; Colotta V; Varano F; Calabri FR; Filacchioni G; Galli A; Costagli C; Carlà V
J Med Chem; 2004 Jan; 47(1):262-72. PubMed ID: 14695840
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists.
Colotta V; Catarzi D; Varano F; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Traini C; Pugliese AM; Pedata F; Morizzo E; Moro S
Bioorg Med Chem; 2008 Jun; 16(11):6086-102. PubMed ID: 18468446
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
[TBL] [Abstract][Full Text] [Related]
16. Scaffold decoration at positions 5 and 8 of 1,2,4-triazolo[1,5-c]pyrimidines to explore the antagonist profiling on adenosine receptors: a preliminary structure-activity relationship study.
Federico S; Ciancetta A; Porta N; Redenti S; Pastorin G; Cacciari B; Klotz KN; Moro S; Spalluto G
J Med Chem; 2014 Jul; 57(14):6210-25. PubMed ID: 24972108
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists.
Baraldi PG; Cacciari B; Spalluto G; Bergonzoni M; Dionisotti S; Ongini E; Varani K; Borea PA
J Med Chem; 1998 Jun; 41(12):2126-33. PubMed ID: 9622554
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models.
Tafi A; Bernardini C; Botta M; Corelli F; Andreini M; Martinelli A; Ortore G; Baraldi PG; Fruttarolo F; Borea PA; Tuccinardi T
J Med Chem; 2006 Jul; 49(14):4085-97. PubMed ID: 16821770
[TBL] [Abstract][Full Text] [Related]
19. QSAR of adenosine receptor antagonists. Part 3: Exploring physicochemical requirements for selective binding of 1,2,4-triazolo[5,1-i]purine derivatives with human adenosine A3 receptor subtype.
Roy K; Leonard JT; Sengupta C
Bioorg Med Chem Lett; 2004 Jul; 14(14):3705-9. PubMed ID: 15203147
[TBL] [Abstract][Full Text] [Related]
20. Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key study.
Moro S; Braiuca P; Deflorian F; Ferrari C; Pastorin G; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
J Med Chem; 2005 Jan; 48(1):152-62. PubMed ID: 15634009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
